Phase II clinical trials are a critical aspect of the drug development process. With drug development costs ever increasing, novel designs that can improve the efficiency of phase II trials are extremely valuable. Phase II clinical trials for cancer treatments often measure a binary outcome. The final trial decision is generally to continue or cease development. When this decision is based solely on the result of a hypothesis test, the result may be known with certainty before the planned end of the trial. Unfortunately though, there is often no opportunity for early stopping when this occurs. Some existing designs do permit early stopping in this case, accordingly reducing the required sample size and potentially speeding up drug develo...
[[abstract]]The success rate of drug development has been declined dramatically in recent years and ...
This paper introduces a decision-theoretic design for a series of phase II trials. Instead of design...
continuous endpoints Wong-Shian Huang,a,by Jen-pei Liu,b,cy and Chin-Fu Hsiaob The success rate of d...
Randomised controlled trials are considered the gold standard in trial design. However, phase II onc...
Two-stage designs that allow for early stopping if the treatment is ineffective are commonly used in...
Abstract background The pace of novel medical treatments and approaches to therapy has accelerated i...
Abstract Background Phase II cancer studies are undertaken to assess the activity of a new drug or a...
AbstractThe Simon two-stage optimal design is often used for phase II cancer clinical trials. A stud...
Objectives: In phase II clinical trials in oncology, the potential efficacy of a new treatment regim...
Because the sample size is varying while the estimate of sample size is changing, the quality of an ...
The Simon two-stage optimal design is often used for phase II cancer clinical trials. A study procee...
Most statistical methodology for phase III clinical trials focuses on the comparison of a single exp...
Phase II studies in oncology have evolved over the previous several decades. Currently, the number o...
Phase II oncology trials are conducted to evaluate whether the tumour activity of a new treatment is...
Phase II clinical trials aim to potentially screen out ineffective and identify effective therapies ...
[[abstract]]The success rate of drug development has been declined dramatically in recent years and ...
This paper introduces a decision-theoretic design for a series of phase II trials. Instead of design...
continuous endpoints Wong-Shian Huang,a,by Jen-pei Liu,b,cy and Chin-Fu Hsiaob The success rate of d...
Randomised controlled trials are considered the gold standard in trial design. However, phase II onc...
Two-stage designs that allow for early stopping if the treatment is ineffective are commonly used in...
Abstract background The pace of novel medical treatments and approaches to therapy has accelerated i...
Abstract Background Phase II cancer studies are undertaken to assess the activity of a new drug or a...
AbstractThe Simon two-stage optimal design is often used for phase II cancer clinical trials. A stud...
Objectives: In phase II clinical trials in oncology, the potential efficacy of a new treatment regim...
Because the sample size is varying while the estimate of sample size is changing, the quality of an ...
The Simon two-stage optimal design is often used for phase II cancer clinical trials. A study procee...
Most statistical methodology for phase III clinical trials focuses on the comparison of a single exp...
Phase II studies in oncology have evolved over the previous several decades. Currently, the number o...
Phase II oncology trials are conducted to evaluate whether the tumour activity of a new treatment is...
Phase II clinical trials aim to potentially screen out ineffective and identify effective therapies ...
[[abstract]]The success rate of drug development has been declined dramatically in recent years and ...
This paper introduces a decision-theoretic design for a series of phase II trials. Instead of design...
continuous endpoints Wong-Shian Huang,a,by Jen-pei Liu,b,cy and Chin-Fu Hsiaob The success rate of d...